AMP Stock Analysis: Amplifon S.p.A | MI
Medical Distribution | MI, Italy | Market Cap: 3.138m EUR | 12M Return: -23.7% | IT0004056880 | Charts, Fundamentals & Technical Analysis
Avg Turnover: 12.5M
EPS Trend: -71.9%
Qual. Beats: 0
Rev. Trend: 92.4%
Qual. Beats: 0
Warnings
Tailwinds
No distinct edge detected
Seasonality 11.6 years of data
How good or bad each month usually is (without trend). The score below shows how much you can trust it: 0 = pure chance, >40 gets interesting and >55 is strong.
Amplifon S.p.A. is a global distributor of hearing solutions and customized hearing products, operating across Europe, the Middle East, Africa, the Americas, and the Asia Pacific. Founded in 1950 and headquartered in Milan, Italy, the company supports customers through audiological care services (Ampli-care), a smartphone application for device management, and proprietary product lines such as Ampli-power and Ampli-mini hearing devices.
As classified under the GICS Health Care Distributors sub-industry, Amplifons business model is primarily retail-driven rather than manufacturing-focused, with revenue generated through the sale and fitting of hearing aids and related audiology services to end consumers. The hearing solutions market is shaped by demographic trends such as an aging population, and hearing aids are typically classified as regulated medical devices subject to national healthcare reimbursement schemes in many of the companys operating regions.
- Aging demographics globally drive structural hearing aid demand growth
- Americas and Asia Pacific organic growth outpaces mature European core market
- M&A pipeline and store expansion fuel top-line and margin scaling
| Net Income: 101.2m TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.07 > 0.02 and ΔFCF/TA -0.84 > 1.0 |
| NWC/Revenue: -17.51% < 20% (prev -17.95%; Δ 0.44% < -1%) |
| CFO/TA 0.10 > 3% & CFO 414.8m > Net Income 101.2m |
| Net Debt (-228.1m) to EBITDA (568.3m): -0.40 < 3 |
| Current Ratio: 0.73 > 1.5 & < 3 |
| Outstanding Shares: last quarter (265.7m) vs 12m ago 18.15% < -2% |
| Gross Margin: 54.88% > 18% (prev 56.50%; Δ -1.62% > 0.5%) |
| Asset Turnover: 59.33% > 50% (prev 62.75%; Δ -3.42% > 0%) |
| Interest Coverage Ratio: 4.45 > 6 (EBIT TTM 260.7m / Interest Expense TTM 58.6m) |
| A: -0.10 (Total Current Assets 1.16b - Total Current Liabilities 1.59b) / Total Assets 4.32b |
| B: 0.25 (Retained Earnings 1.08b / Total Assets 4.32b) |
| C: 0.06 (EBIT TTM 260.7m / Avg Total Assets 4.09b) |
| D: 0.54 (Book Value of Equity 1.51b / Total Liabilities 2.81b) |
| Altman-Z'' = 1.17 = BB |
| DSRI: 1.04 (Receivables 229.0m/220.3m, Revenue 2.43b/2.42b) |
| GMI: 1.03 (GM 56.50% / 54.88%) |
| AQI: 0.90 (AQ_t 0.57 / AQ_t-1 0.64) |
| SGI: 1.00 (Revenue 2.43b / 2.42b) |
| TATA: -0.07 (NI 101.2m - CFO 414.8m) / TA 4.32b) |
| Beneish M = -3.03 (Cap -4..+1) = AA |
As of September 11, 2026, the stock is trading at EUR 11.35 with a total of 808,816 shares traded. Over the past week, the price has changed by -4.94%, over one month by -6.32%, over three months by +7.69% and over the past year by -23.65%.
Current recommended Stop Loss: 10.70 (which is 5.7% or 2.1 ATR below the current price).
Amplifon S.p.A has no consensus analysts rating.
P/E Trailing = 38.1613
P/E Forward = 12.3001
P/S = 1.1496
P/B = 2.0914
P/EG = 0.3511
Revenue TTM = 2.43b EUR
EBIT TTM = 260.7m EUR
EBITDA TTM = 568.3m EUR
Long Term Debt = 567.8m EUR (from longTermDebt, last quarter)
Short Term Debt = 724.4m EUR (from shortLongTermDebt, last quarter)
Debt = 483.9m EUR (Leases only: 483.9m)
Net Debt = -228.1m EUR (calculated: Debt 483.9m - CCE 712.0m)
Enterprise Value = 2.91b EUR (3.14b + Debt 483.9m - CCE 712.0m)
Interest Coverage Ratio = 4.45 (Ebit TTM 260.7m / Interest Expense TTM 58.6m)
EV/FCF = 9.82x (Enterprise Value 2.91b / FCF TTM 296.4m)
FCF Yield = 10.18% (FCF TTM 296.4m / Enterprise Value 2.91b)
FCF Margin = 12.21% (FCF TTM 296.4m / Revenue TTM 2.43b)
Net Margin = 4.17% (Net Income TTM 101.2m / Revenue TTM 2.43b)
Gross Margin = 54.88% ((Revenue TTM 2.43b - Cost of Revenue TTM 1.10b) / Revenue TTM)
Gross Margin QoQ = 27.23% (prev 22.44%)
Tobins Q-Ratio = 0.67 (Enterprise Value 2.91b / Total Assets 4.32b)
Interest Expense / Debt = 12.11% (Interest Expense 58.6m / Debt 483.9m)
Taxrate = 34.31% (53.0m / 154.4m)
NOPAT = 171.3m (EBIT 260.7m * (1 - 34.31%))
Current Ratio = 0.73 (Total Current Assets 1.16b / Total Current Liabilities 1.59b)
Debt / Equity = 0.32 (Debt 483.9m / totalStockholderEquity, last quarter 1.51b)
Debt / EBITDA = -0.40 (Net Debt -228.1m / EBITDA 568.3m)
Debt / FCF = -0.77 (Net Debt -228.1m / FCF TTM 296.4m)
Total Stockholder Equity = 1.15b (last 4 quarters mean from totalStockholderEquity)
RoA = 2.47% (Net Income 101.2m / Total Assets 4.32b)
RoE = 8.80% (Net Income TTM 101.2m / Total Stockholder Equity 1.15b)
RoCE = 15.17% (EBIT 260.7m / Capital Employed (Equity 1.15b + L.T.Debt 567.8m))
RoIC = 6.56% (NOPAT 171.3m / Invested Capital 2.61b)
WACC = 9.63% (E(3.14b)/V(3.62b) * Re(9.89%) + D(483.9m)/V(3.62b) * Rd(12.11%) * (1-Tc(0.34)))
Discount Rate = 9.89% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: 26.51 | Cagr: 0.20%
[DCF] Terminal Value 71.02% ; FCFF base≈296.8m ; Y1≈297.1m ; Y5≈312.9m
[DCF] Fair Price = 15.94 (EV 4.00b - Net Debt -228.1m = Equity 4.23b / Shares 265.2m; r=9.63% [WACC]; 5y FCF grow -0.35% → 2.50% )
EPS Correlation: -71.86 | EPS CAGR: -7.21% | SUE: 0.19 | # QB: 0
Revenue Correlation: 92.43 | Revenue CAGR: 4.16% | SUE: -0.01 | # QB: 0
EPS current Quarter (2026-09-30): EPS=0.11 | Chg30d=-11.00% | Revisions=-25% | Analysts=4
EPS current Year (2026-12-31): EPS=0.71 | Chg30d=+2.22% | Revisions=+30% | GrowthEPS=-0.0% | GrowthRev=+1.5%
EPS next Year (2027-12-31): EPS=0.88 | Chg30d=+0.73% | Revisions=+70% | GrowthEPS=+23.2% | GrowthRev=+43.5%
[Analyst] Revisions Ratio: +50% (up=12, down=3)